7/27/2019 sindrome nefritik
4/5
4 | Capita Selecta Nefrologie | nummer 2, 2012
46. Walker P.D., Shah S.V. Evidence suggesting a role or
hydroxyl radical in gen-tamicin-induced acute renal ailure in rats.
Journal of Cl inical Investigation 1988,81, 334-41.
47. Zager R.A., Burkhart K. Myoglobin toxicity in proximal human
kidney cells:Roles o Fe, Ca2+, H2O2, and terminal mitochondrial
electron transport.Kidney International 1997,51, 728-38.
48. Sheerin N.S., Sacks S.H., Fogazzi G.B. In vitro
erythrophagocy tosis by renaltubular cells and tubular toxicity by
haemoglobin and iron.Nephrology Dialysis Transplantation 1999,14 ,
1391-7.
49. Zager R.A. Combined mannitol and de eroxamine therapy or
myohemoglo-binuric renal injury and oxidant tubular stress.
Mechanistic and therapeuticimplications. Journal of Cl inical
Investigation 1992,90 , 711-9.
50. Sponsel H.T., Al rey A.C., Hammond W.S., Durr J.A. , Ray C.,
Anderson R.J.E ect o iron on renal tubular epithelial cells.Kidney
International 1996,50 ,436-44.
51. Chen L., Boadle R.A., Harris D.C.H. Toxicity o holotrans
errin but not albu-min in proximal tubule cells in primary culture.
Jour nal of the Ameri can Society of Nephrology 1998,9 , 77-84.
52. Paller M.S., Hedlund B.E. Extracellul ar iron chelators
protect kidney cellsrom hypoxia/reoxygenation.Free Radical Biology
and Medicine 1994,17 ,
597-603.53. De Vries B., Walter S.J., Von Bonsdor L., Wol s
T.G.A.M., Van Heurn L.W.E.,
Parkkinen J., et al. Reduction o circulating redox-active iron
by apotrans err inprotects against renal ischemia-reper usion
injury.Transplantation 2004,77 ,669-75.
54. Hashemieh M., Azarkeivan A., Akhlaghpoor S., Shirkavand A.,
Sheibani K.T2-star (T2*) magnetic resonance imaging or assessment o
kidney ironoverload in thalassemic patients. Archives of Iranian
Medicine 2012,15 , 91-4.
55. LEONARDI P., RUOL A. Renal hemosiderosis in the hemolytic
anemias:diagnosis by means o needle biopsy.Blood 1960,16 ,
1029-38.
56. Qian Q., Nath K.A ., Wu Y., Daoud T.M., Sethi S. Hemolysis
and acute kidneyailure. American Jou rnal of K idney D iseases
2010,56 , 780-4.
57. Schein A., Enriquez C., Coates T.D., Wood J.C. Magnetic
resonance detection o kidney iron deposition in sickle cell
disease: A marker o chronic hemolysis.
Journal of Magnetic Re sonance Imag ing 2008,28 , 698-704.
58. Suzukawa K., Ninomiya H., Mitsuhashi S., Anno I., Nagasawa
T., Abe T.Demonstration o the deposition o hemosiderin in the
kidneys o patientswith paroxysmal nocturnal hemoglobinuria by
magnetic resonance imaging.Internal medicine (Tokyo, Japan) 1993,32
, 686-90.
59. Hsiao P.J., Wang S.C., Wen M.C., Diang L.K., Lin S.H.
Fanconi Syndromeand CKD in a Patient With Paroxysmal Nocturnal
Hemoglobinuria andHemosiderosis. Americ an Journal of K idney
Diseases 2010,55 , e1-e5.
60. Ballarn J., Arce Y., Torra Balcells R., az Encarnacin M.,
Manzarbeitia F.,Ortiz A., et al. Acute renal ailure associated to
paroxysmal nocturnalhaemoglobinuria leads to intratubular
haemosiderin accumulation andCD163 expression.Nephrology Dialysis
Transplantation 2011,26 , 3408-11.
61. Fervenza F.C., Croatt A.J. , Bittar C.M., Rosenthal D.W.,
Lager D.J., Leung N.,et al. Induction o Heme Oxygenase-1 and
Ferritin in the Kidney in Warm
Antibody Hemolytic Anemia. American Journa l of Kidney Diseases
2008,52 ,972-7.
62. Buckalew Jr V.M., Someren A. Renal mani estations o sickle
cell disease. Archives of Interna l Medicine 133 , 660-669. 1974.
Re Type: Abstract
63. Rakow-Penner R., Glader B., Yu H., Vasanawala S. Adrenal and
renal cortico-medullary junction iron deposition in red cell
aplasia.Pediatric Radiology 2010,40 , 1955-7.
64. Buhl L., Muirhead D.E., Prentis P.F. Renal hemosiderosis due
to thalassemia: Alight and electron microscopy study with electron
probe X-ray microanalysis.Ultrastructural Pathology 1993,17 ,
169-83.
65. Rous P. URINARY SIDEROSIS : HEMOSIDERIN GRANULES IN THEURINE
AS AN AID IN THE DIAGNOSIS OF PERNICIOUS ANEMIA,HEMOCHROMATOSIS,
AND OTHER DISEASES CAUSING SIDEROSIS OF
THE KIDNEY. J Exp Med 1918,28 , 645-58.66. Nankivell B.J.,
Boadle R.A., Harris D.C.H. Iron accumulation in human
chronic renal disease. American Journal of Kidney Diseases
1992,20 , 580-4.
67. Wang H., Nishiya K., Ito H., Hosokawa T., Hashimoto K.,
Moriki T. Iron depositionin renal biopsy specimens rom patients
with kidney diseases. American
Journal of Ki dney Di seases 2001,38 , 1038-44.68. Gutirrez E.,
Gonzlez E., Hernndez E., Morales E., Martnez M.A., Usera
G., et al. Factors that determine an incomplete recovery o renal
unctionin macrohematuria-induced acute renal ailure o IgA
nephropathy.Clinical
Journal of the American Soc iety of N ephro logy 2007,2 ,
51-7.69. Yachie A., Niida Y., Wada T., Igarashi N., Kaneda H., Toma
T., et al. Oxidative
stress causes enhanced endothelial cell injur y in human heme
oxygenase-1de ciency. Journal of Cl inical Investigation 1999,103 ,
129-35.
70. Aldudak B., Bayazit A.K., Noyan A., zel A., Anarat A.,
Sasmaz I., et al. Renalunction in pediatric patients withb
-thalassemia major.Pediatric Nephrology
2000,15 , 109-12.71. Michelakakis H., Dimitriou E., Georgakis
H., Karabatsos F., Fragodimitri C.,
Saraphidou J., et al. Iron overload and urinary lysosomal enzyme
levels inb -thalassaemia major.European Journal of Pediatrics
1997,156 , 602-4.
72. Koliakos G., Papachristou F., Koussi A., Peri anis V.,
Tsatra I., Souliou E., etal. Urine biochemical markers o early
renal dys unction are associated withiron overload inb
-thalassaemia.Clinical and Laboratory Haematology 2003,25 ,
105-9.
73. Prinsen B.H.C.M. , De Sain-van der Velden, Kaysen G.A. ,
Straver H.W.H.C.,Van Rijn H.J.M., Stellaard F., et al. Trans errin
synthesis is increased innephrotic patients insu ciently to replace
urinary losses. Journal of the
American Soc iety of N ephro logy 2001,12 , 1017-25.74. Howard
R.L., Buddington B., Al rey A.C. Urinary albumin, trans errin
and
iron excretion in diabetic patients.Kidney Int 1991,40 ,
923-6.75. Lin J.L., Lin-Tan D.T., Hsu K.H., Yu C.C. Environmental
lead exposure and
progression o chronic renal diseases in patients without
diabetes.New England Journal of Medicine 2003,348 , 277-86.
76. Rajapurkar M.M., Hegde U., Bhattacharya A., Alam M.G., Shah
S.V. E ect o De eriprone, an Oral Iron Chelator, in Diabetic and
Non-diabetic Glomerular Disease. Toxicology Mechanisms and Methods
2012, 1-22.
77. Brittenham G.M. Iron-chelating therapy or trans usional iron
overload.New England Journal of Medicine 2011,364 , 146-56.
78. Dubourg L, Laurain C, Ranchin B, Pondarr+ C, Hadj-A+ssa A,
Sigaudo-
Roussel D, et al. De erasirox-induced renal impairment in
children: anincreasing concern or pediatricians. Pediatric
Nephrology. In press 2012.
79. Kontoghiorghes G.J. A record o 1320 suspect, de
erasirox-related, patientdeaths reported in 2009: Insu cient
toxicity testing, low e cacy and lack o transparency may endanger
the lives o iron loaded patients.Hemoglobin 2011,35 , 301-11.
80. Huang X.P., Thiessen J.J., Spino M., Templeton D.M.
Transport o ironchelators and chelates across MDCK cell monolayers:
Implications or ironexcretion during chelation
therapy.International Journal of Hematology 2010,91, 401-12.
81. Abbas M., Nawaz R., Shahid M., Nawaz M., Alim M., Asi M.R.
Evaluationo urinary excretion and renal clearance o de eriprone,
creatinine, ironand zinc in human. Asi an Journa l of Che mis try
21, 4583-4592. 2009.
Re Type: Abstract82. Rheault M.N., Bechtel H., Neglia J.P.,
Kashtan C.E. Reversible Fanconi syn-
drome in a pediatric patient on de erasirox.Pediatric Blood and
Cancer 2011,56 , 674-6.
83. Baum M. Renal Fanconi syndrome secondary to de erasirox:
Where thereis smoke there is re. Journal of Pediatric Hemato logy
/Oncology 2010,32 ,525-6.
84. Boutaud O., Roberts II L.J. Mechanism-based therapeutic
approaches torhabdomyolysis-induced renal ailure.Free Radical
Biology and Medicine 2011,51, 1062-7.
85. Rachidi S., Musallam K.M., Taher A.T. A closer look at
paroxysmal nocturnalhemoglobinuria.European Journal of Internal
Medicine 2010,21, 260-7.
86. Tolosano E., Fagoonee S., Morello N., Vinchi F., Fiorito V.
Heme scavenging
and the other acets o hemopexin. Antiox idant s and Redox
Signaling 2010,12 , 305-20.
7/27/2019 sindrome nefritik
5/5
| 5IJzer en nierschade
87. Levy A.P., Asleh R., Blum S., Levy N.S., Miller-Lotan R.,
Kalet-Litman S., etal. Haptoglobin: Basic and clinical aspects.
Antioxidants and Redox Signaling 2010,12 , 293-304.
88. Tracz M.J., Alam J., Nath K.A. Physiology and
pathophysiology o heme:Implications or kidney disease. Jou rnal of
the American Soc iet y of Nephrology 2007,18 , 414-20.
89. Nath K.A., Vercellotti G.M., Grande J.P., Miyoshi H., Paya
C.V., Manivel J.C.,et al. Heme protein-induced chronic renal
infammation: Suppressive e ecto induced heme ox ygenase-11.Kidney
Int 2001,59 , 106-17.
90. Wei Q., Hill W.D., Su Y., Huang S., Dong Z. Heme oxygenase-1
inductioncontributes to renoprotection by G-CSF during
rhabdomyolysis-associatedacute kidney injury. American Journal of
Physi ology Renal Phys iology 2011,301 , F162-F170.
91. Van Gorp H., Delputte P.L., Nauwynck H.J . Scavenger
receptor CD163, aJack-o -all-trades and potential target or
cell-directed therapy.Molecular Immunology 2010,47 , 1650-60.
92. Swinkels D.W., Janssen M.C.H., Bergmans J., Marx J.J.M.
Hereditary hemo-chromatosis: Genetic complexity and new diagnostic
approaches.Clinical Chemistry 2006,52 , 950-68.
93. Brissot P., Ropert M., Le Lan C., Loral O. Non-trans errin
bound iron:A key role in iron overload and iron toxicity.Biochimica
et Biophysica
Acta General S ubjec ts 2012,1820 , 403-10.94. Shah S.V.,
Rajapurkar M.M. The role o labile iron in kidney disease and
treatment with chelation.Hemoglobin 2009,33 , 378-85.95. Pawar
R.D., Pitashny M., Gindea S., Tieng A.T., Levine B., Goilav B., et
al.
Neutrophil gelatinase-associated lipocalin is instrumental in
the pathogenesiso antibody-mediated nephritis in mice. Arthr itis
and Rheumat ism 2012,64 ,1620-31.
96. Lipton P. Ischemic cell death in brain neurons.Physiological
Reviews 1999,79 , 1431-568.
97. Voogd A., Sluiter W., Van Eijk H.G., Koster J.F. Low
molecular weight iron andthe oxygen paradox in isolated rat hearts.
Journal of Clin ical Inves tigat ion 1992,90 , 2050-5.
98. Haase M., Bellomo R., Haase-Fielit z A. Novel Biomarkers,
Oxidative Stress,and the Role o Labile Iron Toxicity in
Cardiopulmonary Bypass-Associated
Acute Kidney Injury. Journal of the American Coll ege of
Cardiology 2010,55 ,2024-33.
99. Mishra J., Qing M.A., Prada A., Mitsne es M., Zahedi K.,
Yang J., et al.Identi cation o neutrophil gelatinase-associated
lipocalin as a novel earlyurinary biomarker or ischemic renal
injury. Journal of the American Soc iety of Nephrology 2003,14 ,
2534-43.
100. Ho J., Lucy M., K rokhin O., Hayglass K., Pascoe E.,
Darroch G., et al.Mass Spectrometry-Based Proteomic Analysis o
Urine in Acute KidneyInjury Following Cardiopulmonary Bypass: A
Nested Case-Control Study.
American Journal of K idney D iseases 2009,53 , 584-95.101. Ho
J., Reslerova M., Gali B., Gao A., Bestland J., Rush D.N., et al.
Urinary hep-
cidin-25 and risk o acute kidney injury ollowing cardiopulmonary
bypass.Clinical Journal of the American Society of Nephrology 6 ,
2340-2346. 2011.Re Type: Abstract
102. Haase-Fielitz A., Mertens P.R., Plab M., Kuppe H., Hetzer
R., WestermanM., et al. Urine hepcidin has additive value in ruling
out cardiopulmonarybypass-associated acute kidney injury: An
observational cohort study.Critical Care 2011,15 .
103. Prowle J.R., Ostland V., Calzavacca P., Licari E., Ligabo
E.V., EcheverriJ.E., et al. Greater increase in urinary hepcidin
predicts protection romacute kidney injury a ter cardiopulmonary
bypass.Nephrology Dialysis Transplantation 2011.
104. Prowle J.R., Westerman M., Bellomo R. Urinary hepcidin: An
inverse bio-marker o acute kidney injury a ter cardiopulmonary
bypass?Current Opinion in Critical Care 2010,16 , 540-4.
105. Kozyraki R., Fy e J., Verroust P.J., Jacobsen C.,
utry-Varsat A., Gburek J., etal. Megalin-dependent cubilin-mediated
endocytosis is a major pathway
or the apical uptake o trans errin in polarized
epithelia.Proceedings of the National Academy of Sciences of the
United States of America 2001,98 ,12491-6.
106. Barasch J, Qiu A, inventors; Mutant NGAL proteins and uses
thereo . NewYork/United S tates patent WO/2011/149962. 2011 Dec
1.
107. Shah S.V. Evidence suggesting a role or hydroxyl radical in
passive Heymannnephritis in rats. Americ an Jo urnal of Physio logy
Renal Physiology 1988,254 , F337-F344.
108. Ellis D. Anemia in the course o the nephrotic syndrome
secondary to trans-errin depletion.The Journal of Pediatrics
1977,90 , 953-5.
